ScholarIQanswers from OpenAlex & ORCID
L. Puig
ResearcherPublications, citations & collaboration network
L. Puig is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does L. Puig have?
ScholarIQindexed works
L. Puig has 990 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does L. Puig have?
ScholarIQcitation count
L. Puig has 29,812 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of L. Puig?
ScholarIQh-index
L. Puig has an h-index of 76 in OpenAlex.
What is the i10-index of L. Puig?
ScholarIQi10-index
L. Puig has an i10-index of 450 in OpenAlex.
What is the ORCID of L. Puig?
ScholarIQorcid
The ORCID for L. Puig is on the source record.
What is the OpenAlex record for L. Puig?
ScholarIQopenalex
The OpenAlex for L. Puig is on the source record.
What are the most-cited papers on L. Puig?
ScholarIQmost cited works
Epidemiology of atopic dermatitis in adults: Results from an international survey
S. Barbarot, S. Auziere, A. Gadkari, Giampiero Girolomoni, L. Puig, Eric L. Simpson, David J. Margolis, Marjolein de Bruin‐Weller, Laurent Eckert
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth B. Gordon, Jolanta Węgłowska, L. Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco A. Kerdel, April W. Armstrong, Georg Stingl, Alexa B. Kimball, H. Bachelez, Jashin J. Wu, Jeffrey Crowley, Richard G. Langley, Tomasz Blicharski, C. Paul, J.‐P. Lacour, Stephen K. Tyring, Leon Kircik, Sergio Chimenti, Kristina Callis Duffin, Jerry Bagel, John Koo, Gary Aras, Joanne Li, Wenjie Song, Cassandra E. Milmont, Yifei Shi, Ngozi Erondu, Paul Klekotka, Brian L. Kotzin, Ajay Nirula
Psoriasis and Systemic Inflammatory Diseases: Potential Mechanistic Links between Skin Disease and Co-Morbid Conditions
Batya B. Davidovici, Naveed Sattar, Prinz C. Jörg, L. Puig, Paul Emery, Jonathan N. Barker, Peter van de Kerkhof, Mona Ståhle, Frank O. Nestlé, Giampiero Girolomoni, James G. Krueger
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim Papp, Howard Sofen, L. Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin Valdes, Elizabeth H. Thompson, H. Bachelez
Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
Mark Lebwohl, H. Bachelez, Jonathan Barker, Giampiero Girolomoni, Arthur Kavanaugh, Richard G. Langley, C. Paul, L. Puig, Kristian Reich, P.C.M. van de Kerkhof